This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Small Cell Lung Cancer
This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
-
Highlands Oncology Group, Springdale, Arkansas, United States, 72762
Providence Medical Foundation, Fullerton, California, United States, 92835
David Geffen School of Medicine, Los Angeles, California, United States, 90095
Ucsf Mount Zion Medical Ctr, San Francisco, California, United States, 94115
University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center, Miami, Florida, United States, 33136
Adventhealth Cancer Insitute, Orlando, Florida, United States, 32804
H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa, Florida, United States, 33612
Rush University Medical Center, Chicago, Illinois, United States, 60612
Baptist Health Lexington, Lexington, Kentucky, United States, 40503
University of Maryland Medical Group, Baltimore, Maryland, United States, 21201
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Daiichi Sankyo,
Global Clinical Director, STUDY_DIRECTOR, Daiichi Sankyo
2029-02-22